Neumora Therapeutics Inc (NMRA): Next-Year EPS Estimate 31.11%
As of 2026-11-12, Neumora Therapeutics Inc (NMRA) has a next-year EPS growth estimate of 31.11%. Featured in 5 EPS revision reports, most recently on 2026-11-06.
On 2026-10-29, analyst consensus for NMRA's next-year EPS growth shifted from 30.06% to 31.11% — a positive change of 1.05 percentage points. The revised estimate has been sustained across 13 subsequent trading sessions. Current-year growth is projected at 37.64%.
What's Driving This
The primary structural driver is the October 29, 2026 analyst revision lifting NMRA’s next-year EPS
Generated 2026-11-03 from news as of 2026-11-03
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 31.11%
- EPS growth this year
- 37.64%
- EPS next quarter (est)
- -$0.20
- Last price
- $0.43
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 31.11% | 37.64% | -$0.20 | $0.43 |
| 2026-11-11 | 31.11% | 37.64% | -$0.20 | $0.47 |
| 2026-11-10 | 31.11% | 37.64% | -$0.20 | $0.47 |
| 2026-11-09 | 31.11% | 37.64% | -$0.20 | $0.49 |
| 2026-11-07 | 31.11% | 37.64% | -$0.20 | $0.50 |
| 2026-11-06 | 31.11% | 37.64% | -$0.20 | $0.50 |
| 2026-11-05 | 31.11% | 37.64% | -$0.20 | $0.49 |
| 2026-11-04 | 31.11% | 37.64% | -$0.20 | $0.57 |
| 2026-11-03 | 31.11% | 37.64% | -$0.20 | $0.57 |
| 2026-11-02 | 31.11% | 37.64% | -$0.20 | $0.50 |
| 2026-10-31 | 31.11% | 37.64% | -$0.20 | $0.37 |
| 2026-10-30 | 31.11% | 37.64% | -$0.20 | $0.37 |
| 2026-10-29 | 31.11% | 37.64% | -$0.20 | $0.39 |
| 2026-10-28 | 30.06% | 37.34% | -$0.20 | $0.39 |
| 2026-10-27 | 30.06% | 37.34% | -$0.20 | $0.37 |
| 2026-10-26 | 30.06% | 37.34% | -$0.20 | $0.39 |
| 2026-10-23 | 30.06% | 37.34% | -$0.20 | $0.38 |
| 2026-10-22 | 30.06% | 37.34% | -$0.20 | $0.41 |
| 2026-10-21 | 30.06% | 37.34% | -$0.20 | $0.42 |
| 2026-10-20 | 30.06% | 37.34% | -$0.20 | $0.47 |
| 2026-10-19 | 30.06% | 37.34% | -$0.20 | $0.47 |
| 2026-10-16 | 30.06% | 37.34% | -$0.20 | $0.47 |
| 2026-10-15 | 30.06% | 37.34% | -$0.20 | $0.43 |
| 2026-10-14 | 30.06% | 37.34% | -$0.20 | $0.35 |
| 2026-10-13 | 30.06% | 37.34% | -$0.20 | $0.37 |
| 2026-10-12 | 30.06% | 37.34% | -$0.20 | $0.44 |
| 2026-10-11 | 30.06% | 37.34% | -$0.20 | $0.48 |
| 2026-10-10 | 30.06% | 37.34% | -$0.20 | $0.48 |
| 2026-10-09 | 30.06% | 37.34% | -$0.20 | $0.48 |
| 2026-10-08 | 30.06% | 37.34% | -$0.20 | $0.48 |
Reports Featuring NMRA
- 2026-11-06
NMRA, REPL Lead Healthcare Surge: EPS Revisions Fuel 20%+ Gains
- 2026-11-05
U Leads 23.5% EPS Revision Rally; REPL, BUR, CSGP Also Surge
- 2026-11-04
NMRA Jumps 46% as EPS Revisions Fuel Biotech Rally; REPL, BUR Follow
- 2026-11-03
NMRA Jumps 46% as Healthcare Small Caps Lead EPS Revision Rally
- 2026-11-02
Healthcare Micro-Caps Lead: COSM +34.8%, NMRA +28.2%, GMAB +25.4% on EPS Revisions
Recent News
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Neumora Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Neumora Therapeutics Inc (NMRA) has a next-year EPS growth estimate of 31.11%, based on analyst consensus.
When was the latest EPS estimate revision for NMRA?▾
The most recent revision occurred on 2026-10-29, when analysts adjusted the next-year EPS growth estimate from 30.06% to 31.11%.
What sector and industry does Neumora Therapeutics Inc belong to?▾
Neumora Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NMRA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Neumora Therapeutics Inc (NMRA) appears here because it was detected by our daily top-EPS-revision-performer screen.